pCDCAR1 EGFRvIII h(OXζ)(CAR-MZ068)
The vector of anti-EGFRvIII chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human EGFRvIII. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFRvIII antibody linked to OX40 and CD3ζ signaling domains. And the vector product was designed for the treatment of Human glioblastoma (GBM).
Targeting Cell Type
Human glioblastoma (GBM)
Discription of Signaling Cassetes
OX40, also known as CD134 or TNFRSF4 is a member of the TNFR-superfamily of receptors which is not constitutively expressed on resting naïve T cells, unlike CD28. OX40 is a secondary co-stimulatory immune checkpoint molecule, expressed after 24 to 72 hours following activation. The interaction between OX40 and its binding partner, OX40L (CD252) plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells and modulate cytokine receptor signaling. OX40 cosignaling in CAR improve redirected T-cell effector functions and enhance anti-tumor activity.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
Epidermal growth factor receptor
ERBB; HER1; mENA; ERBB1; PIG61; NISBD2
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-EGFRvIII (13.1.2) h(CD28-41BB-CD3ζ) CAR, pCDCAR1
||Anti-EGFR scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1
||Anti-EGFRvIII (MR1-1) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-EGFR (Cetuximab) h(CD28-41BB-CD3ζ) CAR, pCDCAR1
||Oncolytic Adenovirus (Capsid modified Ad5, phTERT-Δ55k, Anti-EGFR-7), Viral particle
||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ19k, Anti-EGFR), Viral particle
||Lenti-EGFR CAR (scFv-CD28) Viral Particle
||Lenti-EGFR CAR (scFv-CD3ζ, Nimotuzumab) Viral Particle
||Oncolytic Adenovirus (Capsid modified Ad5, pCMV-Δ55k, Anti-EGFR-6), Viral particle
||Anti-EGFR scFv h(CD28) CART, pCDCAR1